SOURCE: Equity News Circuit

Equity News Circuit

April 30, 2013 08:20 ET

Free Research Reports on GWAY, HNT, MDSO and PLX Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwired - Apr 30, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Greenway Medical Technologies, Inc. (NYSE: GWAY) shares plunged 22.87 percent on volume of 1.35 million shares traded Monday to close at $12.38 a share. The company has revised its guidance for fiscal 2013. Revenues are now expected to be in the range of $132 million to $134 million, down from their previous estimate in mid-February of $145 million to $150 million.

Find out more about Greenway Medical Technologies including full access to the free equity report at: www.ParagonReport.com/GWAY

Health Net, Inc. (NYSE: HNT) shares spiked 4.62 percent on more than three times the average daily volume Monday to close at $29.45 a share. The company swung to a GAAP net income of approximately $50.1 million, or $0.62 per diluted share, for the first quarter of 2013, compared to a GAAP loss of $26.6 million, or a loss of $0.32 per share, a year ago.

Find out more about Health Net including full access to the free equity report at: www.ParagonReport.com/HNT

Medidata Solutions Inc. (NASDAQ: MDSO) shares surged 20.77 percent on volume of 1.21 million shares traded Monday to close at $65.29 a share. The company reported record revenues of $63.3 million for the first quarter of 2013, an increase of 26 percent when compared to the year ago quarter.

Find out more about Medidata Solutions including full access to the free equity report at: www.ParagonReport.com/MDSO

Protalix BioTherapeutics Inc. (NYSE: PLX) shares spiked 2.36 percent on more than double the average daily volume Monday to close at $5.64 a share. The company announced that UPLYSO has been granted regulatory approval in Mexico and Chile for the treatment of Gaucher disease.

Find out more about Protalix BioTherapeutics including full access to the free equity report at: www.ParagonReport.com/PLX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information